Adenomyomatous Hyperplasia of the Ampulla of Vater Masquerading as Malignancy: A Case Series

2014 ◽  
Vol 109 ◽  
pp. S290
Author(s):  
Patrick Hickey ◽  
Saba Ahmad ◽  
Matthew Sullivan ◽  
Jeffrey Brodsky ◽  
Hiral Shah
Keyword(s):  
Case Series ◽  
Ampulla Of Vater ◽  
Adenomyomatous Hyperplasia

scholarly journals Adenomyomatous hyperplasia of the ampulla of Vater presenting as acute pancreatitis

2014 ◽  
Vol 2014 (mar06 1) ◽  
pp. bcr2013203151-bcr2013203151 ◽  
Author(s):  
Rafiullah ◽  
S. Tanimu
Keyword(s):  
Acute Pancreatitis ◽  
Ampulla Of Vater ◽  
Adenomyomatous Hyperplasia

Gangliocytic Paraganglioma of the Ampulla of Vater: Case Series and a Systematic Review

2013 ◽  
Vol 108 ◽  
pp. S572
Author(s):  
Tossapol Kerdsirichairat ◽  
Mustafa Arain ◽  
Rajeev Attam ◽  
Juan Manivel ◽  
Martin Freeman
Keyword(s):  
Systematic Review ◽  
Case Series ◽  
Ampulla Of Vater ◽  
Gangliocytic Paraganglioma

scholarly journals Impact of Standardized Allergen-RemovedRhus vernicifluaStokes Extract on Advanced Adenocarcinoma of the Ampulla of Vater: A Case Series

2013 ◽  
Vol 2013 ◽  
pp. 1-8 ◽  
Author(s):  
Woncheol Choi ◽  
Soomin An ◽  
Eunmi Kwon ◽  
Wankyu Eo ◽  
Sanghun Lee
Keyword(s):  
Evaluation Criteria ◽  
Case Series ◽  
Progression Free Survival ◽  
Final Analysis ◽  
Complete Response ◽  
Ampulla Of Vater ◽  
Free Survival ◽  
Rhus Verniciflua ◽  
Rare Malignancy

Background. Adenocarcinoma of the ampulla of Vater (AAV) is a rare malignancy that has a better prognosis than other periampullary cancers. However, the standard treatment for patients with relapsed or metastatic AAV has not been established. We investigated the clinical feasibility of standardized allergen-removedRhus vernicifluastokes (aRVS) extract for advanced or metastatic AAV.Patients and Methods. From July 2006 to April 2011, we retrospectively reviewed all patients with advanced AAV treated with aRVS extract alone. After applying inclusion/exclusion criteria, 12 patients were eligible for the final analysis. We assessed the progression-free survival (PFS) and overall survival (OS) of these patients during the follow-up period.Results. The median aRVS administration period was 147.0 days (range: 72–601 days). The best tumor responses according to Response Evaluation Criteria in Solid Tumors were as follows: two with complete response, two with stable disease, and eight with progressive disease. The median OS was 15.1 months (range: 4.9–25.1 months), and the median PFS was 3.0 months (range: 1.6–11.4 months). Adverse reactions to the aRVS treatment were mostly mild and self-limiting.Conclusions. Prolonged survival was observed in patients with advanced AAV under the treatment of standardized aRVS extract without significant adverse effects.

Ampulla of Vater Carcinoma in Real-World Clinical Practice: A Case Series

2015 ◽  
Vol 101 (3) ◽  
pp. e75-e78 ◽  
Author(s):  
Jacopo Giuliani ◽  
Paolo Piacentini ◽  
Andrea Bonetti
Keyword(s):  
Clinical Practice ◽  
Real World ◽  
Case Series ◽  
Ampulla Of Vater

scholarly journals Adenomyomatous Hyperplasia of Ampulla of Vater and a Concomitant Renal Tumor: A Case Report

Cureus ◽  
2021 ◽  
Author(s):  
Luisa Frutuoso ◽  
Ana Marta Pereira ◽  
Lucia Carvalho ◽  
Gil Gonçalves ◽  
Mário Nora
Keyword(s):  
Case Report ◽  
Renal Tumor ◽  
Ampulla Of Vater ◽  
Adenomyomatous Hyperplasia

scholarly journals Carcinoid tumors of the duodenum and the ampulla of Vater: Current diagnostic and therapeutic approach in a series of 8 patients. Case series

2011 ◽  
Vol 9 (3) ◽  
pp. 248-253 ◽  
Author(s):  
George C. Nikou ◽  
Christos Toubanakis ◽  
Konstantinos G. Moulakakis ◽  
Spiridon Pavlatos ◽  
Christos Kosmidis ◽  
...  
Keyword(s):  
Therapeutic Approach ◽  
Case Series ◽  
Ampulla Of Vater ◽  
Carcinoid Tumors

Adenomatous Papilloma of Ampulla of Vater

1950 ◽  
Vol 14 (3) ◽  
pp. 425-427 ◽  
Author(s):  
Mark C. Wheelock ◽  
Arthur J. Atkinson ◽  
James M. Tucker
Keyword(s):  
Ampulla Of Vater
Sign in / Sign up

Export Citation Format

Share Document